Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110016/S094

FlexAbility Ablation Catheter; FlexAbilityTM Ablation Catheter, Sensor EnabledTM

ABBOTT MEDICAL · Decision date Jun 5, 2026

FDA DECISIONP110016/S094

What did the FDA decide?

FDA records P110016/S094 as a supplement to PMA P110016, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 5, 2026.

FDA approval order statement

supplier process improvements and alternative sourcing for two catheter actuation components
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 5, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P110016/S094
Regulatory pathway
PMA supplement
Product code
OAD
Decision code
OK30
Decision date
Jun 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.

Product code
OAD
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P110016/S089 · Related supplement

    FlexAbility Ablation Catheter, Sensor Enabled

  2. P110016/S091 · Related supplement

    FlexAbility Ablation Catheter (Flex) and FlexAbility Ablation Catheter, Sensor Enabled (Flex SE)

  3. P110016/S092 · Related supplement

    FlexAbility and FlexAbility Sensor Enabled

  4. P110016/S093 · Related supplement

    FlexAbility Ablation Catheter (Flex) and FlexAbility Ablation Catheter, Sensor Enabled (Flex SE)

  5. P110016/S094 received

    Application receipt date recorded by FDA.

  6. P110016/S094 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P110016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110016

Explore the linked device profile

Other records with product code OAD

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Irvine Biomedical,Inc.(Ibi)PMA supplementSep 3, 2026FDA
Biosense Webster, Inc.PMA supplementSep 2, 2026FDA
Ampere GeneratorP040042/S059
Irvine Biomedical,Inc.(Ibi)PMA supplementAug 7, 2026FDA
Ampere GeneratorP060019/S059
Irvine Biomedical, Inc.PMA supplementAug 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
2375 Morse Ave., Plymouth, MN, 55442

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records